| Literature DB >> 26949186 |
Mattia Bonsignori1, Tongqing Zhou2, Zizhang Sheng3, Lei Chen2, Feng Gao1, M Gordon Joyce2, Gabriel Ozorowski4, Gwo-Yu Chuang2, Chaim A Schramm3, Kevin Wiehe1, S Munir Alam1, Todd Bradley5, Morgan A Gladden5, Kwan-Ki Hwang5, Sheelah Iyengar5, Amit Kumar5, Xiaozhi Lu5, Kan Luo5, Michael C Mangiapani5, Robert J Parks5, Hongshuo Song5, Priyamvada Acharya2, Robert T Bailer2, Allen Cao2, Aliaksandr Druz2, Ivelin S Georgiev6, Young D Kwon2, Mark K Louder2, Baoshan Zhang2, Anqi Zheng2, Brenna J Hill2, Rui Kong2, Cinque Soto2, James C Mullikin7, Daniel C Douek2, David C Montefiori8, Michael A Moody9, George M Shaw10, Beatrice H Hahn10, Garnett Kelsoe11, Peter T Hraber12, Bette T Korber12, Scott D Boyd13, Andrew Z Fire13, Thomas B Kepler14, Lawrence Shapiro15, Andrew B Ward4, John R Mascola2, Hua-Xin Liao1, Peter D Kwong16, Barton F Haynes17.
Abstract
Antibodies with ontogenies from VH1-2 or VH1-46-germline genes dominate the broadly neutralizing response against the CD4-binding site (CD4bs) on HIV-1. Here, we define with longitudinal sampling from time-of-infection the development of a VH1-46-derived antibody lineage that matured to neutralize 90% of HIV-1 isolates. Structures of lineage antibodies CH235 (week 41 from time-of-infection, 18% breadth), CH235.9 (week 152, 77%), and CH235.12 (week 323, 90%) demonstrated the maturing epitope to focus on the conformationally invariant portion of the CD4bs. Similarities between CH235 lineage and five unrelated CD4bs lineages in epitope focusing, length-of-time to develop breadth, and extraordinary level of somatic hypermutation suggested commonalities in maturation among all CD4bs antibodies. Fortunately, the required CH235-lineage hypermutation appeared substantially guided by the intrinsic mutability of the VH1-46 gene, which closely resembled VH1-2. We integrated our CH235-lineage findings with a second broadly neutralizing lineage and HIV-1 co-evolution to suggest a vaccination strategy for inducing both lineages.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26949186 PMCID: PMC4826291 DOI: 10.1016/j.cell.2016.02.022
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582